Key Takeaways
- Single oral molecule activating both GLP-1 and amylin receptors
- Phase 1 data: ~13.1% weight loss in only 12 weeks
- Phase 2 is underway — results expected 2025–2026
- FDA approval unlikely before 2029–2030 at earliest
- This is a drug to watch — not to wait for
- Many drugs with strong early signals fail in later trials
What Is Amycretin?
Amycretin is developed by Novo Nordisk (maker of Ozempic, Wegovy, and CagriSema). It is a unimolecular dual agonist — a single chemical structure designed to activate both the GLP-1 receptor and the amylin receptor simultaneously.
CagriSema achieves a similar dual-pathway approach using two separate drugs in one injection. Amycretin attempts this with a single oral pill — technically more challenging but potentially simpler for patients.
Phase 1 is the earliest possible stage of human clinical testing. Its primary purpose is safety and dose-finding — not proving efficacy. Sample sizes are very small (typically 20–60 people). The 13.1% weight loss figure at 12 weeks is an extraordinary early signal, but it needs to replicate in Phase 2 (larger, longer trials) before it means anything definitive. Many drugs with strong Phase 1 signals do not survive later trials.
How Amycretin Compares
| Amycretin | CagriSema | Orforglipron | Wegovy | |
|---|---|---|---|---|
| Form | Oral pill | Weekly injection | Oral pill | Weekly injection |
| Mechanism | GLP-1 + Amylin (1 molecule) | GLP-1 + Amylin (2 drugs) | GLP-1 only | GLP-1 only |
| Phase | Phase 2 | Phase 3 | Phase 3 | Approved |
| Est. approval | 2029–2030 | 2026–2027 | 2026–2027 | Approved |
| Available now | No | No | No | Yes |
Realistic Timeline
| Milestone | Estimated Timing |
|---|---|
| Phase 2 results | 2025–2026 |
| Phase 3 launch (if Phase 2 succeeds) | 2026–2027 |
| Phase 3 completion | 2028–2029 |
| Earliest FDA approval | 2029–2030 |
| Note | Assumes no safety or efficacy setbacks in Phase 2 or 3 |
See where amycretin sits in the full approval timeline or compare it against all pipeline drugs at the comparison hub. Explore the future GLP-1 medications hub.
Frequently Asked Questions
What is amycretin?
Amycretin is an investigational oral drug by Novo Nordisk that combines GLP-1 and amylin receptor agonism in a single molecule — one pill targeting two hormonal pathways simultaneously.
What were amycretin's Phase 1 results?
Phase 1 tablet data showed approximately 13.1% body weight loss over just 12 weeks — an unusually strong early signal. Phase 1 is the earliest stage of human testing with very small sample sizes, primarily focused on safety.
When will amycretin be available?
Phase 2 is underway. Realistically, FDA approval is unlikely before 2029–2030. Many drugs do not survive Phase 2 or Phase 3.
Is amycretin the same as CagriSema?
They share a similar concept — both target GLP-1 and amylin pathways — but differently. CagriSema is two separate drugs in one injection. Amycretin is a single oral molecule designed to activate both receptors simultaneously.
What should I do now?
Amycretin is multiple years from potential availability. FDA-approved medications like tirzepatide (Zepbound) and semaglutide (Wegovy) are available now with strong clinical evidence.
Don't Wait 4+ Years
Amycretin is a drug to watch — not to wait for. FDA-approved options achieving 15–22% weight loss are available through telehealth providers right now.
Take Quiz — Free